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Alcoholic liver disease (ALD) encompasses hepatic steatosis, which may progress to
alcoholic hepatitis, fibrosis, and cirrhosis. It remains a leading cause of morbidity and
mortality in the US and worldwide. The severity of liver disease correlates with plasma
levels of bacterial products in patients, and experimental ALD depends on the level of
gut derived bacterial products in rodents. Since intestinal decontamination and deficiency
of bacterial product receptors or their downstream signaling molecules protect from
alcohol-induced liver disease, bacterial translocation (BT), qualitative, and quantitative
changes of the enteric microbiome are considered as being of fundamental importance
in the pathogenesis of ALD. Recent enhancements in diagnostic technologies provide a
better insight into these shifts. This review highlights vital events in ALD such as BT, the
importance of Toll-like receptor (TLR) signaling, intestinal bacterial overgrowth (IBO), and
changes in the intestinal microbiome. Furthermore, a treatment trial section of patients
reviews possible future options of therapy for ALD modifying the enteric microbiome.
Keywords: alcoholic liver disease, microbiome, bacterial translocation, bacterial overgrowth, bacterial dysbiosis,
steatohepatitis
INTRODUCTION
Liver cirrhosis is the 12th leading cause of death in the United
States, and 48% of all cirrhotic deaths are alcohol-related (Yoon
and Yi, 2010). Hepatic steatosis or fatty liver is the most com-
mon hepatic phenotype of alcoholic liver disease (ALD) and is
characterized by excessive fat accumulation in hepatocytes. It may
progress to alcoholic hepatitis, fibrosis, and cirrhosis (Adachi
and Brenner, 2005; Tilg and Day, 2007). Hepatocyte injury and
infiltration of the liver by inflammatory cells including neu-
trophils are found in alcoholic hepatitis. Finally, alcoholic fibrosis
is characterized by excessive accumulation of extracellular matrix
proteins, most commonly in response to inflammation of the
liver. Advanced liver fibrosis may lead to cirrhosis, liver failure,
and portal hypertension. In many cases, liver transplantation
is needed. Fatty liver can be reversed within a few weeks of
abstinence (Lieber et al., 1965). However, it constitutes a risk
factor for progression to fibrosis and cirrhosis in patients with
severe steatosis that continue to consume alcohol (Sorensen et al.,
1984; Teli et al., 1995). The risk of developing liver cirrhosis
increases with elevated alcohol intake. An augmented risk was
established in men with a daily alcohol intake above 60–80 g and
in women above 20 g. Yet, only 6–41% of the subjects with exces-
sive alcohol consumption develop cirrhosis (Mandayam et al.,
Abbreviations: ALD, alcoholic liver disease; BT, bacterial translocation; FXR,
farnesoid X receptor; IBO, intestinal bacterial overgrowth; IL, interleukin;
LPS, lipopolysaccharide; MHE, minimal hepatic encephalopathy; PAMPs,
pathogen-associated molecular patterns; Reg3, regenerating islet-derived 3; SIBO,
small intestinal bacterial overgrowth; TLR, Toll-like receptor; TNF, tumor necrosis
factor.
2004). 46% of all patients with decompensated cirrhosis at the
time of diagnosis die within 2 years (D’Amico et al., 2006).
Mortality from ALD has been decreasing in recent years, likely
due to improvements in clinical management of common com-
plications including portal hypertension and bleeding esophageal
varices (Paula et al., 2010). Nevertheless, a Danish study found
27- and 35-fold excessive mortality from alcoholic cirrhosis in
men and women, respectively (Kamper-Jorgensen et al., 2004).
The infection-attributed mortality in general of bacterial infec-
tions in cirrhotic patients has been reported to be 30–50% which
could be caused by residing intestinal bacteria as in spontaneous
bacterial peritonitis (SBP) or by non-intestinal bacteria as in res-
piratory tract infections or in tuberculosis with an overall similar
fatality (Christou et al., 2007; Arvaniti et al., 2010). Infections in
subjects with cirrhosis—all causes combined—increase mortality
by 4-fold; 30% of patients succumb to bacterial infections within
the first month and another 30% die by 1 year (Arvaniti et al.,
2010).
There is strong evidence for a gut-liver axis that is causatively
linked not only to progression of alcohol-induced liver disease
but also to infections, both in patients and experimental animal
models.
This review highlights central events in ALD such as bacte-
rial translocation (BT), Toll-like receptor (TLR) stimulation via
bacterial ligands and consequent steps, intestinal bacterial over-
growth (IBO), and dysbiosis, as well as clinical trials of various
treatment modalities of patients with ALD. It additionally refers
to other etiologies of liver disease and the implication of the
microbiome/bacteria therein.
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BACTERIAL TRANSLOCATION
BT is defined as migration of viable bacteria or bacterial prod-
ucts from the gastrointestinal tract through the epithelium to
mesenteric lymph nodes or other extraintestinal organs (Berg
and Garlington, 1979). BT is initiated when there is damage
to the epithelium (Mathurin et al., 2000; Parlesak et al., 2000;
Keshavarzian et al., 2001; Rao et al., 2004; Purohit et al., 2008).
In Caco-2 cell layers and intestinal biopsies, it has been demon-
strated that acetaldehyde, an indirect oxidized metabolite of alco-
hol, disrupts the intestinal barrier (Rao, 1998; Basuroy et al.,
2005; Purohit et al., 2008). Ethanol administration results in
acute damage of the colonic epithelial barrier through acetalde-
hyde (metabolized by the intestinal flora) in rats and subse-
quently activates mast cells (Ferrier et al., 2006). In humans,
ethanol intake leads to duodenal and jejunal mucosal injury
(Bode and Bode, 2003). Lipopolysaccharide (LPS), a critical
component of the outer membrane of Gram-negative bacte-
ria (Fadl et al., 2005), induces macrophages to release pro-
inflammatory cytokines resulting in liver injury (French, 2001).
Pro-inflammatory cytokines such as IL-1β and tumor necrosis
factor (TNF) have been shown to be elevated in the distal ileum
of mice fed with ethanol for 2 weeks (Fleming et al., 2001). They
are also known to disrupt the intestinal barrier (Wang et al.,
2005; Clayburgh et al., 2006; Al-Sadi et al., 2008). This impair-
ment has been demonstrated in duodenal biopsies of cirrhotic
patients, which shows enlarged intercellular spaces below the tight
junctions (Such et al., 2002). In another study, the augmented
intestinal permeability existed longer than 14 days after having
eschewed drinking ethanol (Bjarnason et al., 1984). In sum-
mary, these findings indicate that morphologic and functional
changes may persist in the gut barrier after long-term alcohol
abuse similar to lasting structural and functional alterations in
the liver.
To assess the quantity of BT, bacterial products (also called
pathogen-associated molecular patterns or PAMPs) or viable
bacteria can be measured in the portal or systemic circula-
tion. Plasma LPS levels were elevated in patients with alcoholic
steatohepatitis and alcoholic cirrhosis (Bode et al., 1987; Fukui
et al., 1991; Schafer et al., 2002). There is a direct association
between ethanol administration and increased plasma LPS in
animal models (Nanji et al., 1993; Adachi et al., 1995; Tamai
et al., 2000). Equally in patients, endotoxemia is present in
early stage of ALD prior to the onset of fibrosis or cirrho-
sis (Parlesak et al., 2000; Bode and Bode, 2005). The severity
of liver injury positively correlates with plasma LPS levels in
patients with cirrhosis (Lin et al., 1995), which could also be
related to a decreased clearance of endotoxin from the blood
by the liver (Satoh et al., 2008). Interestingly, plasma LPS is
higher in subjects with alcoholic cirrhosis than in subjects with
cirrhosis from other causes (Bode et al., 1987; Fukui et al.,
1991). Peptidoglycan, the major component of Gram-positive
bacterial cell walls, is higher in rat plasma following acute
ethanol feeding (Tabata et al., 2002). Bacterial DNA, a surro-
gate marker of BT, is higher in cirrhotic rats (Guarner et al.,
2006). BT even precedes IBO and intestinal dysbiosis in ALD (Yan
et al., 2011) similarly to CCl4-induced liver injury (Fouts et al.,
2012).
The innate immune system has conserved pattern recognition
receptors, e.g., TLRs, that recognize specific PAMPs such as LPS,
peptidoglycan, lipoproteins, lipoteichoic acid, double-stranded
RNA, and unmethylated DNA (Akira et al., 2006). TLR2 is impor-
tant in detecting Gram-positive bacteria and recognizes a number
of bacterial components such as lipoproteins, peptidoglycan, and
lipoteichoic acid (Aliprantis et al., 1999; Schwandner et al., 1999;
Yoshimura et al., 1999). According to one study, cirrhotic patients
with ascites had an increased risk of developing SBP in the pres-
ence of a specific TLR2 genotype (16934 TT genotype) or a TLR2
GT microsatellite polymorphism; presence of both risk factors
further augmented the susceptibility for SBP (Nischalke et al.,
2011).
The cellular receptor for endotoxin is TLR4, which plays a
central role in the innate immune response to BT. After bind-
ing of LPS to its cellular receptor TLR4, MyD88-dependent
and MyD88-independent (TRIF/IRF-3-dependent) pathways are
activated. TLR4 mutant C3H/Hej mice and TLR4 knock-out
mice had mitigated hepatic steatosis, inflammation and necro-
sis in ALD compared to wild type mice (Uesugi et al., 2001;
Hritz et al., 2008). TLR4 signaling is important in both BM-
derived cells including Kupffer cells, and endogenous liver cells
including hepatic stellate cells (HSCs) for alcohol-induced hepa-
tocyte injury, steatosis, inflammation, and fibrogenesis (Inokuchi
et al., 2011). Activation of the MyD88- independent, TRIF/IRF-3-
dependent pathway in the liver plays a major role in experimental
ALD (Hritz et al., 2008; Petrasek et al., 2011). A compara-
ble significance of TLR4 for liver fibrogenesis has been noted
in cholestatic or toxic liver fibrosis in mice (Seki et al., 2007).
Other reports indicate a similar implication of TLR4 in non-
alcoholic steatohepatitis in rodents (Ye et al., 2012). The impli-
cation of TLR4 in liver disease has also been proven in human
subjects: it is one of seven genes linked to an elevated risk
of developing cirrhosis in patients with chronic hepatitis C
(Huang et al., 2007). Specific single nucleotide polymorphisms
(TLR D299G and T399I) are associated with less hepatic fibro-
sis by decreased TLR4-mediated signaling (Guo et al., 2009).
Similarly, mice deficient in TLR9, a recognition receptor acti-
vated by CpG motifs specific to bacterial DNA, are protected
from hepatic fibrosis (Gabele et al., 2008). Deficiency in clus-
ter of differentiation 14 (CD14) as cellular co-receptor for LPS
protects from alcohol-induced liver injury (Yin et al., 2001).
Similarly, CD14 knockout mice are resistant to liver injury
from experimental cholestasis and NASH (Isayama et al., 2006;
Imajo, 2011). Lastly, selective intestinal decontamination with
antibiotics results in a decline in plasma LPS and consequently,
this results in an attenuated liver damage in preclinical ani-
mal models of ALD (Adachi et al., 1995; Enomoto et al., 1999,
2001).
Following LPS binding to TLR4 and the initiation of intracel-
lular downstream signaling, a complex interplay occurs between
innate immune cells and other cells of the body via the induc-
tion of cytokines and chemokines. It comprises the migration of
inflammatory cells into the liver, such as neutrophils, leukocytes,
monocytes, and macrophages. Recruited hepatic macrophages
and resident Kupffer cells play a key role in the pathogenesis of
ALD because inactivation of Kupffer cells through gadolinium
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chloride injections largely alleviates alcohol-induced liver disease
(Adachi et al., 1994; Koop et al., 1997). During hepatic inflam-
mation, Kupffer cells produce a large variety of cytokines such
as TNF-α, IL-6, IL-1, chemokines such as KC (CXCL1), MIP-2
(CXCL2), MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4),
and RANTES (CCL5), and reactive oxygen species (Seki and
Schnabl, 2012). In addition, they also produce pro-fibrogenic
mediators, such as TGF-β and PDGF which activate quiescent
HSCs to produce extracellular matrix proteins (Bataller and
Brenner, 2005). Oxidative stress via alcohol and acetaldehyde
sensitizes HSC to activation by LPS and consequent induction
of hepatic fibrosis (Quiroz et al., 2001; Karaa et al., 2008).
Similarly to Kupffer cells, HSC upon LPS stimulation express
pro-inflammatory cytokines (e.g., TNF-α, IL-6) and chemokines
such as CXCL1 (Schwabe et al., 2003; Seki et al., 2007). In
hepatocytes, LPS can promote apoptosis, especially in conjunc-
tion with other hepatotoxic agents (Nagaki et al., 1999; Kudo
et al., 2009). Thus, endotoxin affects Kupffer cells, hepatocytes,
and HSC to participate in the initiation and progression of
ALD.
The detailed role of the adaptive immune system for the initia-
tion and progression of ALD remains largely unknown (Gao and
Bataller, 2011).
Thus, BT not only contributes to increased infection rates
and mortality in end-stage liver disease but also to disease
progression in early stages of alcoholic liver injury and dis-
ease. Viable bacteria need to translocate from the intestine
to extraintestinal sites to cause infections, while translocation
of bacterial products is sufficient to cause disease progression
in ALD.
INTESTINAL BACTERIAL OVERGROWTH
OVERGROWTH OF INTESTINAL BACTERIA IN EXPERIMENTAL ALD
The human intestine harbors 1013 bacteria, a quantity that out-
numbers the total sum of cells in the human body of 1012
(Guarner and Malagelada, 2003; O’Keefe, 2008). The impressive
density of 103 microbial cells/g contents in the jejunum mounts
up to 10 11cells/g contents in the colon (Savage, 1977). Mice
fed with alcohol via an intragastric feeding tube for 3 weeks
show IBO (Yan et al., 2011). Both aerobic and anaerobic bac-
teria increase predominantly in the small intestine (Yan et al.,
2011). IBO correlates well with increased BT. For example, exper-
imentally induced IBO leads to BT and subsequent liver injury
(Lichtman et al., 1990). On the other hand, selective intestinal
decontamination decreases BT and plasma LPS, and amelio-
rates the detrimental effect of LPS on the liver (Adachi et al.,
1995; Enomoto et al., 1999, 2001). Bacterial overgrowth and BT
are also common characteristics observed in end-stage liver dis-
ease (Parks et al., 1996; Guarner et al., 1997). Cirrhotic rats
with BT have been shown with increased bacterial overgrowth
(Runyon et al., 1994; Garcia-Tsao et al., 1995; Sanchez et al.,
2005). Taken together, bacterial overgrowth in the intestine occurs
already in an early stage of experimental ALD. In addition to
alcohol, other experimental etiologies of liver disease, such as
cholestasis, toxic, and non-alcoholic fatty liver disease, are accom-
panied by IBO (Wigg et al., 2001; Miele et al., 2009; Fouts et al.,
2012).
INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH ALD
There are different diagnostic tests to detect IBO in patients.
Aside from D-Xylose test where D-xylose is ingested and then
measured in the urine and blood (Craig and Atkinson, 1988;
Craig and Ehrenpreis, 1999), there are other breath tests used
in the diagnosis of IBO. Hydrogen breath tests are based on
the fact that the only source for hydrogen gas in human intes-
tine is bacterial metabolism of carbohydrates (Levitt, 1969). For
these tests, carbohydrates are ingested and the intestinal bacte-
ria metabolize carbohydrates into hydrogen that will be detected
in the breath. The most frequently used substrates for diagnosis
of IBO are glucose (Metz et al., 1976; Kerlin and Wong, 1988)
and lactulose (Rhodes et al., 1979; Simren and Stotzer, 2006).
Tests with labeled carbon take advantage of the bacteria’s abil-
ity to deconjugate bile acids. For example in the glycocholic acid
breath test, 14C glycocholic acid is administered and the 14CO2 is
then measured (Donald et al., 1992). However, the gold standard
to prove small-intestinal bacterial overgrowth (SIBO) is cultur-
ing of jejunal aspirates of bacteria to demonstrate at least 105
colony forming units/ml (Kerlin and Wong, 1988; Bauer et al.,
2000; Simren and Stotzer, 2006).
Similar to findings in animal models, human subjects with
SIBO exhibit an increased intestinal permeability (Riordan et al.,
1997; Miele et al., 2009). It is now well-established that IBO
occurs more commonly in patients with ALD. Aerobic and anaer-
obic bacteria are increased in jejunal aspirates from subjects with
long-term alcohol use (Bode et al., 1984; CasafontMorencos et al.,
1996). SIBO is more frequent in cirrhotic patients and directly
correlates with the severity of liver damage (Casafont Morencos
et al., 1996; Bauer et al., 2001; Pande et al., 2009; Jun et al., 2010).
Equally, a higher prevalence of antibodies directed against bacte-
rial products is noted in more advanced liver disease (Papp et al.,
2010).
Several hypotheses have been raised to explain the patho-
genesis of bacterial overgrowth: impaired bile flow, intestinal
dysmotility, less acidic gastric pH, and altered intestinal innate
immune response.
Impaired bile flow
In experimental mouse models, the antimicrobials angiogenin 1
and RNAse family member 4 were found to be targets of the
nuclear receptor FXR in intestinal epithelial cells, the receptor for
bile acids. A decrease in these antimicrobials is associated with
IBO (Inagaki et al., 2006). Oral feeding of bile acids to rats with
cirrhosis has been shown to reverse bacterial overgrowth in the
intestine and to lower BT and plasma LPS levels (Lorenzo-Zuniga
et al., 2003). Hence, the markedly decreased bile acid secretion
in cirrhotic patients into the intestine (Raedsch et al., 1983) may
contribute to IBO.
Intestinal dysmotility
Ethanol decreases intestinal motility which may in turn cause
luminal bacteria to proliferate (Bode and Bode, 2003). Patients
with cirrhosis tend to have prolonged orocecal transit time
(Madrid et al., 1997; Chang et al., 1998; Gunnarsdottir et al.,
2003). Similarly, SIBOwith a delayed transit time was noted more
commonly in cirrhotic subjects with hepatic encephalopathy
www.frontiersin.org October 2012 | Volume 3 | Article 402 | 3
Hartmann et al. Microbiome and gut leakiness in ALD
(Gupta et al., 2010). On the other hand, cisapride, a pro-motility
drug, increases small intestinal motility and thereby suppresses
bacterial proliferation in cirrhotic patients (Madrid et al., 2001).
Altered gastric pH
Hypochlorhydria has been linked to IBO in the jejunum of
subjects with cirrhosis (Shindo et al., 1993; Bauer et al.,
2001). Use of proton pump inhibitors in patients with cirrho-
sis increases the risk of suffering SBP (Bajaj et al., 2009). Thus,
impaired bile flow, intestinal dysmotility and less acidic gastric
pH, either separately or in a more intertwined fashion, pro-
mote bacterial overgrowth and further leads to development
of ALD.
Altered intestinal innate immune response
As stated earlier, host antimicrobial molecules are an integral part
of the intestinal innate immune system that regulates the total
bacterial burden, distribution, and composition in the intestine.
These bactericidal proteins are secreted from Paneth cells and
intestinal epithelial cells. Regenerating islet derived (Reg)-3b and
Reg3g, two of the bactericidal proteins, have been found to be
suppressed in murine and human small intestine after ethanol
feeding and chronic alcohol abuse, respectively (Yan et al., 2011).
Administration of prebiotics has been shown to restore Reg3g
protein levels, and this helps to reverse bacterial overgrowth and
to ameliorate experimental alcoholic steatohepatitis.
Thus, quantitative changes in the intestinal microflora predis-
pose to BT and can be strongly considered a contributing factor
to the progression of ALD.
ENTERIC MICROBIOME
INTESTINAL DYSBIOSIS IN EXPERIMENTAL ALD
The intestine provides residence to a variety of microbial com-
munities consisting of 10 different bacterial phyla with more
than 15,000 species-level bacterial phylotypes (Camp et al., 2009).
The most abundant of these phylotypes in mice and humans are
Firmicutes and Bacteroidetes (Eckburg et al., 2005; Ley et al.,
2006; Yan et al., 2011). In a healthy state, the intestinal microflora
keeps a symbiotic relationship with its host. The total bac-
terial burden, distribution, and composition are regulated by
the host’s immune system via intestinal antimicrobial proteins.
Dysbiosis is known as an imbalance between enteric microbial
colonies and its associated deleterious effects on the colonized
host (McLoughlin and Mills, 2011), and this has been implicated
in diseases including inflammatory bowel disease (Frank et al.,
2007). Only a minority of intestinal bacteria can be cultured by
conventional culture techniques, but rapid advances in analytic
methods have intensely enlarged our ability to study biodiver-
sity in a microbial community (Eckburg et al., 2005; Gill et al.,
2006). Offering a first glimpse into alcoholic enteric dysbiosis by
using Length Heterogeneity PCR (LH-PCR) fingerprinting, one
study noted a significantly changed intestinal microbiome in rats
after 10 weeks of ethanol administration (Mutlu et al., 2009). It
reports that probiotic or prebiotic treatment protected alcohol fed
rodents from intestinal dysbiosis. Another study that performed
deep DNA pyrosequencing of bacterial 16S rRNA after 3 weeks
of continuous intragastric ethanol administration showed sig-
nificant intestinal dysbiosis in alcohol fed mice. Dysbiosis was
characterized by a profound suppression of several endogenous
probiotic bacteria such as Lactobacillus (Yan et al., 2011). This
is especially noteworthy as several studies have demonstrated a
beneficial effect of Lactobacillus supplementation in experimental
ALD (Nanji et al., 1994; Forsyth et al., 2009; Mutlu et al., 2009).
The question arises as to whether an alcohol-associated micro-
biome inmice is specific for alcohol or similar changes can be also
observed in other experimental liver disease models. In cholesta-
sis, 16S rRNA sequencing could not show a significant qualitative
change in the microbiome relative to control mice. In mice with
CCl4-induced toxic liver injury, dysbiosis could be observed with
an elevated intestinal burden of Firmicutes and Actinobacteria
(Fouts et al., 2012). In contrast to microbial changes in ALD,
obesity-induced fatty liver seems to be associated with an aug-
mented bacterial load of Firmicutes and a relative decrease in
Bacteroidetes (Ley et al., 2005; Turnbaugh et al., 2009). Although
experimental liver disease models depend on translocated bacte-
rial products from the intestine, there are distinct changes in the
enteric microbiome of four different experimental etiologies of
liver disease.
INTESTINAL DYSBIOSIS IN PATIENTS WITH ALD
As mentioned above, the two most abundant bacterial phyla
in the intestine of humans are Firmicutes and Bacteroidetes
(Eckburg et al., 2005; Ley et al., 2006). According to one
study, Bacteroidetes were found to be significantly reduced and
Proteobacteria and Fusobacteria highly enriched in patients
with cirrhosis related to hepatitis B and alcohol abuse (Chen
et al., 2011). Specifically, the families Lachnospiraceae (Chen
et al., 2011) and Ruminococcaceae were decreased in patients
with cirrhosis, whereas Enterobacteriaceae, Alcaligeneceae, and
Fusobacteriaceae were significantly higher (Bajaj et al., 2012). In
another study, a significant decrease in various Lactobacilli was
demonstrated in human subjects with hepatitis B virus-related
decompensated cirrhosis or liver transplant for hepatitis B cir-
rhosis (Wu et al., 2011). This might potentially explain why
administration of Lactobacillus is beneficial in certain types of
liver injury (Kirpich et al., 2008; Vajro et al., 2011). Recently,
Bacteroidacea from the phylum Bacteroidetes have been found
to be decreased in patients with chronic alcohol abuse compared
to healthy controls (Mutlu et al., 2012). Compared to non-
dysbiotic subjects, alcoholics with dysbiosis had smaller intestinal
quantities of Bacteroidetes and higher levels of Proteobacteria.
Contrary to the findings in experimental ALD in mice (Yan et al.,
2011), the two aforementioned studies demonstrated a reduc-
tion of intestinal Bacteroidetes in patients with (at least partly)
alcohol-induced cirrhosis (Chen et al., 2011; Mutlu et al., 2012).
This difference might be due to a later stage of liver disease
in patients and increased heterogeneity of patient population
in these human studies as compared to well-controlled animal
studies. In addition, different methods for sample collection, stor-
age, DNA extraction, and sequencing might also explain these
differences.
Many of the translational human microbiome studies are
descriptive in nature. To advance the field and link changes in
the microbiome to onset and progression of disease, further
metagenomic, transcriptomic, and in particular metabolomic
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studies are urgently needed. It is conceivable that not only translo-
cation of PAMPs contributes to ALD, but changes in bacterial
metabolites further modify liver disease.
THE MICROBIOME AS TARGET IN ALCOHOLIC LIVER DISEASE
An intricate interaction exists between bowel flora and liver
in ALD. Alteration of normal bowel flora and significant over-
growth of harmful bacteria are described in animal models and
humans with liver disease. These bacteria release endotoxins that
increase damage to the integrity of gut flora and activate certain
inflammatory pathways that lead to progression of alcohol liver
disease (Forsyth et al., 2009). High endotoxin environment stim-
ulates secretion of cytokines such as TNF-α, IL-1, and IL-6 that
influence the development of liver fibrosis and cirrhosis (Gratz
et al., 2010). Gut bacteria play a major role in the pathogenesis
of ALD, and there are human trial studies that have shown that
antibiotics and probiotics are effective in reducing the number
of gram-negative bacteria and altering the gut flora to prevent
further alcohol-induced liver injury and liver fibrosis. In addition,
studies have demonstrated in human trials that use of probiotics
can improve liver function by decreasing oxidative damage/stress,
improving neutrophil function, and reducing endotoxin
levels.
Antibiotics
Antibiotics have shown to provide beneficial effects in animal
models with liver disease. Prophylactic use of antibiotics in
patients with chronic liver disease is an established method of
preventing infections in upper gastrointestinal hemorrhage and
recurrent SBP (Leber et al., 2012). A randomized controlled
trial showed that long-term prophylactic use of ciprofloxacin
reduced the 1 year mortality rate in cirrhotic patients with
low ascitic protein levels and without prior SBP episode (Terg
et al., 2008). Similarly, a double blind, multi-center, placebo-
controlled study investigating the long-term efficacy of nor-
floxacin in cirrhotic patients who had survived a previous
episode of SBP found a significant reduction of the risk of
SBP recurrence in the treated group at 1 year of follow-up
(Gines et al., 1990).
Despite the established role of antibiotics in patients with
hepatic encephalopathy, there are few human trials that have
demonstrated the positive role of antibiotics in patients with
ALD. According to one randomized controlled trial by Madrid
et al., nine patients with alcoholic cirrhosis were treated with
antibiotics that consisted of norfloxacin and neomycin during a
period of 6 months. There was improvement of Child-Pugh sta-
tus at 3 and 6 months treatment period (Madrid et al., 2001).
Thus, long-term antibiotic treatment may improve the progno-
sis of ALD and result in a higher survival of cirrhotic patients.
Despite improvement of liver function and reduction of infec-
tions in patients with ALD, it is also important to consider the
negative effects of antibiotics on the gutmucosa. Prolonged use of
antibiotics can sometimes increase the vulnerability of gut flora
and lead to increased pathogenic bacterial colonization (Brandl
et al., 2008). In addition, it is also important to consider that
continued use of antibiotics can result in heightened bacterial
resistance to these antibiotics and increased virulence of these
pathogens (Novella et al., 1997; Campillo et al., 1998; Fernandez
et al., 2002).
Probiotics
Probiotics are living non-pathogenic microorganisms that cause
the growth of other microorganisms. They possess beneficial
effects on the host by changing the gut microbiota profile, and
this further leads to changes in the gut lumen that promotes
anti-inflammatory effects. This improves gut barrier integrity and
decreases the release of pro-inflammatory products by harmful
bacteria (Forsyth et al., 2009; Gratz et al., 2010). By enhanc-
ing production of anti-inflammatory cytokines and secretion of
antibacterial proteins, this further helps to reduce the produc-
tion and translocation of bacterial endotoxin (Bongaerts et al.,
2005; Forsyth et al., 2009; Gratz et al., 2010; Wang et al.,
2011). Probiotics include lactic acid bacteria such as Lactobacilli,
Lactococci, and Bifidobacteria, or yeasts such as Saccharomyces
cerevisiae (Bongaerts et al., 2005). Probiotics have been shown in
several human clinical trials to prevent recurrent Clostridium dif-
ficile colitis and to maintain remission of pouchitis (Kirpich et al.,
2008).
Probiotics including Lactobacillus and Bifidobacterium species
have been used in human trials to study the beneficial effects
of these microorganisms in patients with ALD. An investigation
by Kirpich et al. consisted of a randomized, prospective study
of 66 alcoholic male patients and 24 healthy, adult male con-
trols concerning the therapeutic role of probiotics in treatment of
ALD (Kirpich et al., 2008). In this study, alcoholic patients had
reduced numbers of Lactobacilli and Enterococci, and increased
number of E. coli. Of the alcoholic patients that received probi-
otics, the depressed numbers of Bifidobacteria, Lactobacilli, and
Enterococci returned to the levels seen in healthy controls. Initial
liver function tests, specifically AST, ALT, and GGT, were signif-
icantly elevated in the alcoholic group. After 5 days of probiotic
therapy, patients treated with probiotics had significantly lower
AST and ALT activity compared to the control group. In the sub-
group of patients with well-defined alcoholic hepatitis, there was
a significant reduction in ALT, AST, GGT, LDH, and total biliru-
bin values after probiotic therapy. The study further emphasizes
that probiotic therapy is associated with greater improvement in
liver enzymes.
Probiotic treatment can also help to restore neutrophil func-
tions in patients with alcoholic cirrhosis. In an open-label
study by Stadlbauer et al., 12 patients with alcoholic cirrhosis
received Lactobacillus casei Shirota three times daily for 4 weeks
(Stadlbauer et al., 2008). This was compared to 13 healthy con-
trols and eight cirrhotic patients that did not receive probiotics.
At baseline, the study showed that alcoholic cirrhotic patients
have reduced neutrophil capacity. However, 28 days of treatment
with L. casei Shirota revealed normalization of phagocytic activ-
ity in patients with alcoholic cirrhosis in the treatment group as
opposed to the control group. The study also demonstrated that
it is safe to administer the probiotics in this group of patients
without adverse events. Another study by Loguercio et al. eval-
uated the effects of chronic therapy with probiotics on patients
with alcoholic liver cirrhosis (Loguercio et al., 2005). In this study,
20 patients with alcoholic liver cirrhosis were treated with the
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probiotic VSL#3, which is a mixture of 450 billion bacteria in var-
ious strains including Streptococcus thermophilus, Bifidobacterium
breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. casei,
and L. bulgaricua for 3 months. Patients treated with probi-
otic therapy presented with significantly reduced plasma levels
of oxidative stress parameters, and there was improvement of
liver function. An improvement of cytokine levels following
treatment of VSL#3 was also noticed. A double-blind placebo-
controlled study by Lata et al. investigated the effect of the
probiotic E. coli Nissle on 34 patients with alcoholic cirrhosis
(Lata et al., 2007). Overall, there was significant improvement
of the intestinal colonization in the group treated with probi-
otics. In addition, an improvement of Child-Pugh Score in alco-
holic cirrhotic patients treated with E. coli Nissle was observed.
Probiotic treatment may improve the prognosis of ALD, but
the effects of probiotics are strain-dependent. Therefore, fur-
ther clinical studies are warranted to determine which probiotic
strain should be used and which patient population should be
treated.
Prebiotics
Prebiotics are complex carbohydrates that cannot be degraded
by pancreatic and intestinal enzymes in the gastrointestinal tract
(Yan et al., 2011). These carbohydrates are ultimately metabo-
lized by gut microflora. Some examples of prebiotics include:
lactulose, fructo-oligosaccharides (FOS), oats, and galacto-oligo-
saccharides (Gibson, 2008; Yan et al., 2011). There is a lack of
current human trials that further elucidate the beneficial effect of
prebiotics on patients with ALD. However, as mentioned above,
there are animal studies that have shown that prebiotics help to
slow liver damage progression. Prebiotics potentially possess ben-
eficial effects in alcohol liver disease by altering the gutmicroflora.
However, additional clinical studies are needed to further clarify
the possible benefits of the use of prebiotic therapy in patients
with ALD.
Synbiotics
Synbiotics are mixtures of pre- and pro-biotics. Rats fed with
synbiotics (L. acidophilus, L. helveticus, and Bifidobacterium in
an enriched medium) displayed significantly diminished endo-
toxemia, BT, and liver damage in the course of acute pancre-
atitis and simultaneous heavy alcohol consumption (Marotta
et al., 2005). A 7 day patient trial revealed a significant ame-
lioration of Indocyanine Green clearance as measures of liver
function in cirrhotic patients treated with synbiotics (Pediacoccus
pentoseceus, Leuconostoc mesenteroides, L. paracasei subspecies
paracasei, and L. plantarum along with bioactive, fermentable
fiber: betaglucan, inulin, pectin, and starch) as opposed to the
placebo-controlled group in which no change was observed
(Riordan et al., 2007). This synbiotic treatment may also result
in an improvement of the Child-Pugh classification with a sig-
nificant improvement in serum bilirubin, albumin concentra-
tions, and international normalized ratio (INR). Furthermore,
administration of the same synbiotics to cirrhotic patients
with minimal hepatic encephalopathy (MHE) leads to signif-
icantly decreased ammonia levels and a reversal of MHE in
50% of the cases (Liu et al., 2004). It was also associated
with significantly lower LPS levels in the blood, as was feed-
ing of fermentable fiber alone. A meta-analysis demonstrated
that synbiotics and both pre- and pro-biotics were associated
with improvement of liver cirrhosis-associated MHE (Shukla
et al., 2011). Amongst the prebiotics, lactulose seems to be
the agent of choice for treatment of cirrhosis-associated MHE.
Rishi et al. compared treatment with synbiotics (L. acidophilus
and inulin) to L. acidophilus (probiotic) and inulin (prebi-
otic) alone, respectively, in Salmonella typhimurium-induced
liver injury (Rishi et al., 2009). Mice fed with synbiotics
were effectively protected against BT, lipid peroxidation, and
liver damage, as were pre- and pro-biotic treated groups.
Nevertheless, none of the observations suggested a synergistic
effect in the synbiotic-supplemented group in this model. Thus,
synbiotics—despite a wide range of composition—seem to alle-
viate liver damage and improve the prognosis in patients with
cirrhosis.
CONCLUSION
ALD remains a leading cause of morbidity and mortality in
the United States and worldwide. Since progression of ALD is
partly driven by inflammatory responses to bacteria and their
products, BT is a central event in the pathogenesis of ALD.
This review highlights several mechanisms which facilitate BT,
i.e., impaired bile flow, intestinal dysmotility, altered gastric pH,
impaired intestinal immunity, and oxidative stress at the intesti-
nal mucosa that increases intestinal permeability. Translocated
bacterial PAMPs, in particular LPS, leads to TLR signaling and
secretion of pro-inflammatory cytokines and chemokines, and
this ultimately enhances alcoholic liver injury and steatohepati-
tis. Linked to BT and crucial in ALD are quantitative changes
in the intestinal microflora. IBO is a driving force in the etiol-
ogy of ALD. Given a leaky gut, overgrowth leads to increased
luminal burden of bacterial products and toxins that can now
traverse the gut barrier and encounter the liver as first organ in
the body. This can be considered a second hit for hepatocytes
that already encounter and metabolize ethanol. Recent advances
in diagnostic technologies such as deep pyrosequencing have
enabled a meticulous investigation of qualitative changes of the
enteric microbiome. By means of these tools, dysbiosis has been
described in preclinical and clinical ALD. Further studies are
necessary to elucidate more clearly the exact impact of qualita-
tive changes in the enteric flora on disease progression. Using
metagenomics, transcriptomics, and metabolomics, future inves-
tigations need to focus on the identification of metabolites that
mediate the effect of orally ingested alcohol to extraintestinal
organs. Although there is promising but limited evidence that
modulation of the microbiome using—biotics mitigate disease
activity in patients, additional clinical studies on perhaps novel
targets are still required before routine use of these agents is
advisable.
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